The Supreme Court will hear final arguments in a landmark case over drug patents that could change the rules for the country's healthcare sector and potentially curb its global role as a supplier of c

Dugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its new florbetaben molecule, a possible Alzheimer's treatment acquired by the company in a deal with Germany's Bayer AG.